3篇
您的检索式：作者名="S. Windecker"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 裸金属支架植入后支架内血栓形成:急诊经皮冠状动脉介入治疗的成功率以及不良预后的预测因素 | Wenaweser P. Rey C. Eberli F. R. S. Windecker 刘少伟 | 2005 | 世界核心医学期刊文摘(心脏病学分册)2005，0，12： | 4 |
| 2 | Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: The Bern–Rotterdam diabetes cohort study显示文摘 | C. Simsek L. R?ber M. Magro E. Boersma Y. Onuma G.G. Stefanini T. Zanchin B. Kalesan P. Wenaweser P. Jüni R.J. van Geuns R.T. van Domburg S. Windecker P.W.J.C. Serruys | 2013 | International Journal of Cardiology2013，，1： | 1 |
| 3 | 西罗莫司洗脱支架与紫杉醇洗脱支架用于冠状动脉血运重建的比较显示文摘Background:Sirolimus-eluting stents and paclitaxel-eluting stents, as compared with bare-metal stents, reduce the risk of restenosis. It is unclear whether there are differences in safety and efficacy between the two types of drug-eluting stents. Methods:We conducted a randomized, controlled, single-blind trial comparing sirolimus-eluting stents with paclitaxel-eluting stents in 1012 patients undergoing percutaneous coronary intervention. The primary end point was a composite of major adverse cardiac events(death from cardiac causes, myocardial infarction, and ischemia-driven revascularization of the target lesion) by nine months. Follow-up angiography was completed in 540 of 1012 patients(53.4 percent). Results:The two groups had similar baseline clinical and angiographic characteristics. The rate of major adverse cardiac events at nine months was 6.2 percent in the sirolimus-stent group and 10.8 percent in the aclitaxel-stent group(hazard ratio, 0.56; 95 percent confidence interval, 0.36 to 0.86; P=0.009). The difference was driven by a lower rate of target-lesion revascularization in the sirolimus-stent group than in the paclitaxel-stent group(4.8 percent vs. 8.3 percent; hazard ratio, 0.56; 95 percent confidence interval, 0.34 to 0.93; P=0.03). Rates of death from cardiac causes were 0.6 percent in the sirolimus stent group and 1.6 percent in the paclitaxel-stent group(P=0.15); the rates of myocardial infarction were 2.8 percent and 3.5 percent, respectively(P=0.49); and the rates of angiographic restenosis were 6.6 percent and 11.7 percent, respectively(P=0.02). Conclusions:As compared with paclitaxel-eluting stents, the use of sirolimus-eluting stents results in fewer major adverse cardiac events, primarily by decreasing the rates of clinical and angiographic restenosis. | Windecker S. Remondino A. Eberli F. R. 姜朝晖 | 2006 | 世界核心医学期刊文摘(心脏病学分册)2006，2，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员